Fresenius Kabi announced the launch of Romidepsin for Injection, the first generic equivalent of Istodax®.
Romidepsin for Injection is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma in adult patients who have received at least 1 prior systemic therapy.
The generic product is supplied as a kit containing a 10mg single-dose vial of romidepsin as a lyophilized powder for reconstitution and a 2.2mL vial of diluent.
“Generic oncology medicines continue to be vitally important to the protocols used in treating many forms of cancer,” said John Ducker, president and CEO of Fresenius Kabi USA. “As a leading US developer and supplier of oncology injectable medicines, Fresenius Kabi remains committed to continuing to expand access to affordable oncology therapies.”
According to the Company, nearly a billion dollars has been invested in US manufacturing and distribution to strengthen the supply chain of essential medicines.
- Romidepsin for Injection available from Fresenius Kabi. News release. Fresenius Kabi. Accessed July 12, 2022. https://www.businesswire.com/news/home/20220712005418/en/Romidepsin-for-Injection-Available-from-Fresenius-Kabi
- Romidepsin for Injection. Package insert. Fresenius Kabi; 2022. Accessed July 12, 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73a2028d-6735-4cd4-b63d-d072df9927a1
This article originally appeared on MPR